New drug cocktail aims to fight stomach cancer when others fail

NCT ID NCT07371871

Not yet recruiting Disease control Sponsor: Anhui Provincial Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a combination of two drugs, TAS-102 and apatinib, as a third-line treatment for advanced gastric cancer. About 30 adults who have already tried two prior treatments will take these pills in cycles. The goal is to see if the combination can shrink tumors and delay cancer growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Trifluridine/Tipiracil (TAS-102) and Apatinib
What this could lead to: If this works, it could offer a new treatment option for people with advanced gastric cancer who have not responded to earlier therapies.
What could go wrong: This is a small, early exploratory study with only 30 participants and no comparison group. The combination may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED GASTRIC CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.